9BK0.F ABL Diagnostics Société anonyme
- Market cap
- EUR 34.7M
- P/E
- 18.0x
- P/B
- 4.89x
- ROE
- 12.9%
- Dividend yield
- 5.09%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 9BK0.F undervalued?
Graham number9BK0.F trades 97.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABL Diagnostics Société anonyme fundamental analysis
No fundamental analysis for ABL Diagnostics Société anonyme yet.
ABL Diagnostics Société anonyme stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABL Diagnostics Société anonyme
ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA, hepatitis-B Virus (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK …
Full company profileABL Diagnostics Société anonyme financial statements
ABL Diagnostics Société anonyme annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 8.75M | 5.61M | 5.33M | 6.95M |
| Gross Profit | -102K | 8.32M | 4.88M | 4.84M | 6.62M |
| Operating Income | -103K | 59.3K | -657K | -484K | 290K |
| EBITDA | - | 651K | 45.4K | 334K | 1.01M |
| Net Income | 258K | 1.11M | 54.4K | 285K | 987K |
| EPS | 0.13 | 0.07 | 0.00 | 0.02 | 0.06 |
| Balance Sheet | |||||
| Total Assets | 2.71M | 15.4M | 14.9M | 11.8M | 13.0M |
| Total Liabilities | 94.3K | 8.65M | 8.14M | 4.32M | 5.32M |
| Shareholders' Equity | 2.62M | 6.75M | 6.77M | 7.49M | 7.63M |
| Cash & Short-term Investments | 2.70M | 1.01M | 2.22M | 469K | 1.08M |
| Cash Flow | |||||
| Operating Cash Flow | -56.7K | - | - | -1.35M | 1.51M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 963K | 793K |
| Free Cash Flow | -56.7K | - | - | -2.32M | 715K |
| Ratios | |||||
| ROE | 9.8% | 16.4% | 0.8% | 3.8% | 12.9% |
| ROA | 9.5% | 7.2% | 0.4% | 2.4% | 7.6% |
| Net Profit Margin | - | 12.6% | 1.0% | 5.3% | 14.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ABL Diagnostics Société anonyme dividends
- Dividend yield
- 5.09%
- Forward dividend
- 0.11 EUR
- Payout ratio
- -
- Ex-dividend date
- Jul 3, 2026
Who owns ABL Diagnostics Société anonyme
- Insiders 93.58%
- Institutions 0.00%
- Public & others 6.43%
- Shares outstanding 16.1M
- Free float 990K
ABL Diagnostics Société anonyme company profile
- Company name
- ABL Diagnostics Société anonyme
- Ticker
- 9BK0.F
- ISIN
- FR001400AHX6
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Information Services
- Employees
- 25
- Fiscal year end
- December
- Address
- 72c, rue de Thionville, Woippy, France, 57140
- Phone
- 33 3 87 17 81 56
- Website
- abldiagnostics.com
About ABL Diagnostics Société anonyme
ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA, hepatitis-B Virus (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK virus (BKV), human papillomavirus (HPV), respiratory syncytial virus (RSV), and salmonella; real time PCR assays; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, next generation sequencing (NGS) library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as ABL Diagnostics Société anonyme and changed its name to ABL Texcell Diagnostics SA in April 2022. The company is headquartered in Woippy, France. ABL Texcell Diagnostics SA operates as a subsidiary of Advanced Biological Laboratories (ABL) S.A.
ABL Diagnostics Société anonyme management
2- Dr. Chalom B. Sayada M.D., Ph.D.GM & Director · born 1965
- Mr. Ronan BoulmeDirector of Regulatory Affairs